» Articles » PMID: 11149951

A Peripheral Marker for Schizophrenia: Increased Levels of D3 Dopamine Receptor MRNA in Blood Lymphocytes

Overview
Specialty Science
Date 2001 Jan 10
PMID 11149951
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Dopamine is a major neurotransmitter in the central nervous system, and its receptors are associated with a number of neuropathological disorders such as Parkinson's disease and schizophrenia. Although the precise pathophysiology of schizophrenia remains unknown, the dopaminergic hypothesis of the illness assumes that the illness results from excessive activity at dopamine synapses in the brain. Because, at present, the diagnosis of schizophrenia relies on descriptive behavioral and symptomatic information, a peripheral measurable marker may enable a simpler, more rapid, and more accurate diagnosis and monitoring. In recent years, human peripheral blood lymphocytes have been found to express several dopamine receptors (D(3), D(4), and D(5)) by using molecular biology techniques and binding assays. It has been suggested that these dopamine receptors found on lymphocytes may reflect receptors found in the brain. Here we demonstrate a correlation between the D(3) dopamine receptor on lymphocytes and schizophrenia and show a significant elevation of at least 2-fold in the mRNA level of the D(3), but not of the D(4), dopamine receptor in schizophrenic patients. This increase is not affected by different antipsychotic drug treatments (typical or atypical). Moreover, nonmedicated patients exhibit the same pattern, indicating that this change is not a result of medical treatment. We propose the D(3) receptor mRNA on blood lymphocytes as a marker for identification and followup of schizophrenia.

Citing Articles

Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia.

Alvarez-Herrera S, Rosel Vales M, Perez-Sanchez G, Becerril-Villanueva E, Flores-Medina Y, Maldonado-Garcia J Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399382 PMC: 10892557. DOI: 10.3390/ph17020167.


Dopamine, Immunity, and Disease.

Channer B, Matt S, Nickoloff-Bybel E, Pappa V, Agarwal Y, Wickman J Pharmacol Rev. 2023; 75(1):62-158.

PMID: 36757901 PMC: 9832385. DOI: 10.1124/pharmrev.122.000618.


Neuroinflammation in Schizophrenia: The Key Role of the WNT/β-Catenin Pathway.

Vallee A Int J Mol Sci. 2022; 23(5).

PMID: 35269952 PMC: 8910888. DOI: 10.3390/ijms23052810.


Tics and Emotions.

Leisman G, Sheldon D Brain Sci. 2022; 12(2).

PMID: 35204005 PMC: 8870550. DOI: 10.3390/brainsci12020242.


The peripheral dopamine 2 receptor antagonist domperidone attenuates ethanol enhancement of dopamine levels in the nucleus accumbens.

Obray J, Jang E, Klomp A, Small C, Richardson A, LeBaron J Alcohol Clin Exp Res. 2022; 46(3):396-409.

PMID: 35040146 PMC: 8920780. DOI: 10.1111/acer.14775.


References
1.
Bondy B, Ackenheil M, Elbers R, Frohler M . Binding of 3H-spiperone to human lymphocytes: a biological marker in schizophrenia?. Psychiatry Res. 1985; 15(1):41-8. DOI: 10.1016/0165-1781(85)90038-1. View

2.
Lieberman J . Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. J Clin Psychiatry. 1999; 60 Suppl 12:9-12. View

3.
Seeman P, Niznik H . Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J. 1990; 4(10):2737-44. DOI: 10.1096/fasebj.4.10.2197154. View

4.
Ferrero P, Rocca P, Eva C, Benna P, Rebaudengo N, Ravizza L . An analysis of lymphocyte 3H-N-methyl-scopolamine binding in neurological patients. Evidence of altered binding in Alzheimer's disease. Brain. 1991; 114 ( Pt 4):1759-70. DOI: 10.1093/brain/114.4.1759. View

5.
Takahashi N, Nagai Y, Ueno S, Saeki Y, Yanagihara T . Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudogenes. FEBS Lett. 1992; 314(1):23-5. DOI: 10.1016/0014-5793(92)81452-r. View